Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05221840
Title	A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)
Acronym	PACIFIC-9
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS